Genomic and multi-omic data analysis
Sequencing gives you a matrix. What a programme actually needs is a defensible biological conclusion, the figures that support it, and analysis someone else can reproduce.
01What this is
From FASTQ to a defensible finding
We take sequencing data from wherever it was produced — your laboratory, a core facility, or a commercial vendor — and return an interpreted written report. Not a folder of plots, and not a spreadsheet of differentially expressed genes with no argument attached.
The work runs from quality control and normalisation through differential expression, enrichment and pathway interpretation, to a written account of what the data supports and, just as importantly, what it does not. Where an analysis choice materially changes the conclusion, that choice is stated and justified rather than buried.
Data types handled
Bulk RNA-seq and single-cell RNA-seq. Whole-genome and whole-exome sequencing. 16S and ITS amplicon sequencing for microbial community and strain work. Legacy microarray data and public dataset reanalysis, including mining GEO and TCGA for signatures relevant to your target.
Tools
PartekFlow for bulk and single-cell workflows, GSEA, ShinyGO and STRING for enrichment and network interpretation, R and Python for anything bespoke, and GraphPad PRISM for statistical presentation. The toolchain follows the question, not the other way around.
02Deliverables
What arrives at the end
- A written report. The finding, the evidence, the caveats, and what it means for the next decision — in language a non-specialist on your board can follow.
- Publication-grade figures. Annotated, captioned, and supplied at resolution suitable for a manuscript or a regulatory submission.
- A methods section. Written so it can be used verbatim, with software versions, parameters, and statistical treatment stated.
- A statistical appendix. Tests used, assumptions checked, multiple-testing correction applied and named.
- The analysis code or workflow. So the result can be reproduced without us. Work that cannot survive that test was not worth commissioning.
03Track record
Where this has been done before
NGS transcriptomic analysis identified NAMPT as a therapeutic target in experimental necrotising enterocolitis, supporting an anti-NAMPT antibody programme — published in Biomedicines, 2024.
Exome sequencing in a pulmonary arterial hypertension cohort surfaced a novel UCHL1 variant, contributing to target validation later published in Circulation, 2024.
RNA-seq interrogation of butyrate-treated colon organoids from normal and APC-mutated FAP patients characterised WNT pathway modulation under IRB approval.
—Also
Related capabilities
Get started
Have data that is not saying what it was supposed to say?
Send the dataset and the question it was meant to answer. A short call is usually enough to tell whether the data can support the conclusion you need.